Compare
Century Therapeutics, Inc. vs ImmunityBio, Inc. vs Agenus Inc vs Sutro Biopharma, Inc.
| Latest fiscal year | Century Therapeutics, Inc. IPSC | ImmunityBio, Inc. IBRX | Agenus Inc AGEN | Sutro Biopharma, Inc. STRO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $109.16M | $113.29M | $114.20M | $102.48M |
| Revenue growth (YoY) | n/m | +668.3% | +10.4% | +65.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -15.8% | -226.0% | -17.7% | -154.5% |
| Net margin | -8.8% | -310.2% | -2.7% | -186.5% |
| Net income | -$9.58M | -$351.40M | -$3.08M | -$191.09M |
| EPS (Diluted) | -$0.14 | -$0.38 | $0.00 | -$22.49 |
| Operating cash flow | -$103.88M | -$304.94M | -$77.19M | -$177.23M |
| Free cash flow | -$104.72M | -$308.78M | -$77.20M | n/a |
| Cash & equivalents | $61.85M | $88.33M | $3.00M | $58.13M |
| Total assets | $223.70M | $501.90M | $226.80M | $173.83M |
| Total liabilities | $64.77M | $1.00B | n/a | $306.28M |
| Shareholders' equity | $158.94M | -$500.47M | -$271.11M | -$132.45M |
| Return on year-end equity | -6.0% | n/a | n/a | n/a |
| Shares outstanding | 87.52M | 1.01B | 35.32M | 8.58M |
Revenue, most recent five fiscal years
| Fiscal year | Century Therapeutics, Inc. | ImmunityBio, Inc. | Agenus Inc | Sutro Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $109.16M Ended 2025-12-31 | $113.29M Ended 2025-12-31 | $114.20M Ended 2025-12-31 | $102.48M Ended 2025-12-31 |
| 1 year earlier | $6.59M Ended 2024-12-31 | $14.74M Ended 2024-12-31 | $103.46M Ended 2024-12-31 | $62.04M Ended 2024-12-31 |
| 2 years earlier | $2.23M Ended 2023-12-31 | $622.0K Ended 2023-12-31 | $156.31M Ended 2023-12-31 | $153.73M Ended 2023-12-31 |
| 3 years earlier | $5.20M Ended 2022-12-31 | $240.0K Ended 2022-12-31 | $98.02M Ended 2022-12-31 | $67.77M Ended 2022-12-31 |
| 4 years earlier | n/a | $934.0K Ended 2021-12-31 | $295.67M Ended 2021-12-31 | $61.88M Ended 2021-12-31 |